Literature DB >> 17928406

Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability.

Melissa L Petreaca1, Min Yao, Yan Liu, Kathryn Defea, Manuela Martins-Green.   

Abstract

Interleukin-8 (IL-8/CXCL8) is a chemokine that increases endothelial permeability during early stages of angiogenesis. However, the mechanisms involved in IL-8/CXCL8-induced permeability are poorly understood. Here, we show that permeability induced by this chemokine requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/fetal liver kinase 1/KDR). IL-8/CXCL8 stimulates VEGFR2 phosphorylation in a VEGF-independent manner, suggesting VEGFR2 transactivation. We investigated the possible contribution of physical interactions between VEGFR2 and the IL-8/CXCL8 receptors leading to VEGFR2 transactivation. Both IL-8 receptors interact with VEGFR2 after IL-8/CXCL8 treatment, and the time course of complex formation is comparable with that of VEGFR2 phosphorylation. Src kinases are involved upstream of receptor complex formation and VEGFR2 transactivation during IL-8/CXCL8-induced permeability. An inhibitor of Src kinases blocked IL-8/CXCL8-induced VEGFR2 phosphorylation, receptor complex formation, and endothelial permeability. Furthermore, inhibition of the VEGFR abolishes RhoA activation by IL-8/CXCL8, and gap formation, suggesting a mechanism whereby VEGFR2 transactivation mediates IL-8/CXCL8-induced permeability. This study points to VEGFR2 transactivation as an important signaling pathway used by chemokines such as IL-8/CXCL8, and it may lead to the development of new therapies that can be used in conditions involving increases in endothelial permeability or angiogenesis, particularly in pathological situations associated with both IL-8/CXCL8 and VEGF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928406      PMCID: PMC2096609          DOI: 10.1091/mbc.e07-01-0004

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  73 in total

1.  IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.

Authors:  I U Schraufstatter; J Chung; M Burger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

2.  Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively.

Authors:  H Zeng; S Sanyal; D Mukhopadhyay
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

3.  A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice.

Authors:  Kristin Ladell; Jochen Heinrich; Marc Schweneker; Karin Moelling
Journal:  J Mol Med (Berl)       Date:  2003-04-04       Impact factor: 4.599

4.  IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.

Authors:  Aihua Li; Seema Dubey; Michelle L Varney; Bhavana J Dave; Rakesh K Singh
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

5.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.

Authors:  S Ugurel; G Rappl; W Tilgen; U Reinhold
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

6.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Authors:  H Gille; J Kowalski; B Li; J LeCouter; B Moffat; T F Zioncheck; N Pelletier; N Ferrara
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

Review 7.  Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo.

Authors:  David J Grainger; Jill Reckless
Journal:  Biochem Pharmacol       Date:  2003-04-01       Impact factor: 5.858

8.  Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor.

Authors:  Lior Zilberberg; Svetlana Shinkaruk; Olivier Lequin; Benoit Rousseau; Martin Hagedorn; Francesco Costa; Dario Caronzolo; Maurice Balke; Xavier Canron; Odile Convert; Georges Laïn; Karine Gionnet; Mario Goncalvès; Mireille Bayle; Lorenzo Bello; Gerard Chassaing; Gérard Deleris; Andreas Bikfalvi
Journal:  J Biol Chem       Date:  2003-07-01       Impact factor: 5.157

9.  IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor.

Authors:  Ingrid U Schraufstatter; Khanh Trieu; Ming Zhao; David M Rose; Robert A Terkeltaub; Meike Burger
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

10.  Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells.

Authors:  Shin-ichiro Miura; Yoshino Matsuo; Keijiro Saku
Journal:  Hypertension       Date:  2003-03-24       Impact factor: 10.190

View more
  77 in total

1.  Dengue hemorrhagic fever-associated immunomediators induced via maturation of dengue virus nonstructural 4B protein in monocytes modulate endothelial cell adhesion molecules and human microvascular endothelial cells permeability.

Authors:  James F Kelley; Pakieli H Kaufusi; Vivek R Nerurkar
Journal:  Virology       Date:  2011-11-29       Impact factor: 3.616

Review 2.  SRC: a century of science brought to the clinic.

Authors:  Alexey Aleshin; Richard S Finn
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

3.  The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8.

Authors:  Eunok Im; Yoon Jeong Choi; Cho Hee Kim; Claudio Fiocchi; Charalabos Pothoulakis; Sang Hoon Rhee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

Review 4.  Chemokine Involvement in Fetal and Adult Wound Healing.

Authors:  Swathi Balaji; Carey L Watson; Rajeev Ranjan; Alice King; Paul L Bollyky; Sundeep G Keswani
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

5.  Profiling of Cytokines Secreted by Conventional Aqueous Outflow Pathway Endothelial Cells Activated In Vitro and Ex Vivo With Laser Irradiation.

Authors:  Jorge A Alvarado; Phuonglan Chau; Jianfeng Wu; Richard Juster; Amde Selassie Shifera; Michael Geske
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 6.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

7.  Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein.

Authors:  Tory P Johnson; Karan Patel; Kory R Johnson; Dragan Maric; Peter A Calabresi; Rodrigo Hasbun; Avindra Nath
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

8.  SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Authors:  Yoshihiro Tokuhisa; Michael E Lidsky; Hiroaki Toshimitsu; Ryan S Turley; Georgia M Beasley; Tomio Ueno; Ketan Sharma; Christina K Augustine; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2013-11-27       Impact factor: 5.344

9.  SCUBE3 regulation of early lung cancer angiogenesis and metastatic progression.

Authors:  Cheng-Hung Chou; Yi-Fang Cheng; Tiing Yee Siow; Amit Kumar; Konan Peck; Chen Chang
Journal:  Clin Exp Metastasis       Date:  2013-02-19       Impact factor: 5.150

10.  Increased serum levels of soluble vascular endothelial-cadherin in patients with systemic vasculitis.

Authors:  Tao Chen; Zai-Pei Guo; Na Cao; Sha Qin; Meng-Meng Li; Rui-Zhen Jia
Journal:  Rheumatol Int       Date:  2014-01-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.